Introduction to biological complexity as a missing link in drug discovery. (3rd August 2018)

• Record Type: Journal Article
• Authors: Gintant, Gary A.; George, Christopher H.
• Is Part Of: Expert opinion on drug discovery. Volume 13:Number 8(2018:Aug.)
• Page Start: 753
• Page End: 763
• Publication Date: 2018-08-03
• Subjects: Drug development -- systems -- complexity -- models -- phenotypic screen -- mechanisms; 615.1
• DOI: 10.1080/17460441.2018.1480608
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : Despite a burgeoning knowledge of the intricacies and mechanisms responsible for human disease, technological advances in medicinal chemistry, and more efficient assays used for drug screening, it remains difficult to discover novel and effective pharmacologic therapies. Areas covered : By reference to the primary literature and concepts emerging from academic and industrial drug screening landscapes, the authors propose that this disconnect arises from the inability to scale and integrate responses from simpler model systems to outcomes from more complex and human-based biological systems. Expert opinion : Further collaborative efforts combining target-based and phenotypic-based screening along with systems-based pharmacology and informatics will be necessary to harness the technological breakthroughs of today to derive the novel drug candidates of tomorrow. New questions must be asked of enabling technologies—while recognizing inherent limitations—in a way that moves drug development forward. Attempts to integrate mechanistic and observational information acquired across multiple scales frequently expose the gap between our knowledge and our understanding as the level of complexity increases. We hope that the thoughts and actionable items highlighted will help to inform the directed evolution of the drug discovery process.